Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



BBI LIFE SCIENCES CORPORATION

BBI生命科學有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1035)

POLL RESULTS OF THE ANNUAL GENERAL MEETING

HELD ON 31 MAY 2017

The board of directors (the "**Board**") of BBI Life Sciences Corporation (the "**Company**") is pleased to announce that the Company held its annual general meeting (the "**AGM**") on 31 May 2017, voting on all the proposed resolutions set out in the notice of the AGM dated 25 April 2017 was taken by way of polling.

As at the date of the AGM, the total number of issued shares of the Company was 544,239,512 shares, which was the total number of shares entitling the shareholders to attend and vote for or against the resolutions proposed at the AGM. No shareholders of the Company who were entitled to attend the AGM abstained from voting in favour of any resolutions proposed at the AGM as set out in Rule 13.40 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules"), nor were any shareholders of the Company required under the Listing Rules to abstain from voting at the AGM.

Computershare Hong Kong Investor Services Limited, the Hong Kong Share Registrar of the Company, was appointed as the scrutineer at the AGM for the purpose of vote-taking. The poll results in respect of the respective resolutions proposed at the AGM are set out as follows:

	ORDINARY RESOLUTIONS		Number of votes	
ORDINART RESOLUTIONS		for	Against	
1	To receive the audited consolidated financial statements and the reports of the directors and auditors for the year ended 31 December 2016.	67,615,500	0	
		(100%)	(0%)	
2	To declare a final dividend for the year ended 31 December 2016.	67,615,500	0	
		(100%)	(0%)	
3(a)	To re-elect Ms. Wang Luojia as executive director of the Company.	67,615,500	0	
		(100%)	(0%)	
3(b)	To re-elect Ms. Wang Jin as executive director of the Company.	67,615,500	0	
		(100%)	(0%)	
3(c)	To re-elect Mr. Ho Kenneth Kai Chung as independent non-executive director of the Company.	50,253,000	17,362,500	
		(74.32%)	(25.68%)	
3(d)	To authorise the Board to fix the respective directors' remuneration.	67,615,500	0	
		(100%)	(0%)	
4	To re-appoint PricewaterhouseCoopers as auditors for the year ending 31 December 2017 and to authorise the Board to fix their remuneration.	67,615,500	0	
		(100%)	(0%)	
5	To grant a general mandate to the directors of the Company to repurchase shares of the Company not exceeding 10% of the number of issued shares of the Company as at the date of passing of this resolution.	67,615,500	0	
		(100%)	(0%)	
6	To grant a general mandate to the directors of the Company to issue, allot and deal with additional shares of the Company not exceeding 20% of the number of issued shares of the Company as at the date of passing of this resolution.	50,253,000	17,362,500	
		(74.32%)	(25.68%)	
		(,270)	(22.0070)	
7	To extend the general mandate granted to the directors of the Company to issue, allot and deal with additional shares of the Company by the number of shares repurchased by the Company.	50,253,000	17,362,500	
		(74.32%)	(25.68%)	

As more than 50% of the votes were cast in favour of each of the resolutions, all of the above ordinary resolutions were approved by the shareholders of the Company

FINAL DIVIDEND FOR THE YEAR ENDED 31 DECEMBER 2016

The Company will pay the final dividend of HK\$0.012 per share for the year ended 31 December 2016 (the "**Dividend**") to shareholders whose names appear on the register of members of the Company on 12 June 2017. It is expected that the dividend warrants will be posted by ordinary mail to shareholders of the Company who are entitled to receive the Dividend at their own risk on 30 June 2017.

By order of the Board

BBI Life Science Corporation

Wang Qisong

Chairman

Hong Kong, 31 May 2017

As at the date of this announcement, the executive directors of the Company are Mr. WANG Qisong, Ms. WANG Luojia, and Ms. WANG Jin; the non-executive director of the Company is Mr. HU Xubo; and the independent non-executive directors of the Company are Mr. XIA Lijun, Mr. HO Kenneth Kai Chung, and Mr. LIU Jianjun.